Adma Biologics Stock Performance
| ADMA Stock | USD 15.83 0.56 3.42% |
The firm shows a Beta (market volatility) of 0.77, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ADMA Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding ADMA Biologics is expected to be smaller as well. At this point, ADMA Biologics has a negative expected return of -0.34%. Please make sure to confirm ADMA Biologics' jensen alpha, potential upside, daily balance of power, as well as the relationship between the treynor ratio and kurtosis , to decide if ADMA Biologics performance from the past will be repeated in the future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days ADMA Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 86.5 M |
ADMA |
ADMA Biologics Relative Risk vs. Return Landscape
If you would invest 1,992 in ADMA Biologics on December 3, 2024 and sell it today you would lose (409.00) from holding ADMA Biologics or give up 20.53% of portfolio value over 90 days. ADMA Biologics is currently does not generate positive expected returns and assumes 2.7635% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than ADMA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ADMA Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ADMA Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ADMA Biologics, and traders can use it to determine the average amount a ADMA Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1222
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ADMA |
Estimated Market Risk
| 2.76 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ADMA Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ADMA Biologics by adding ADMA Biologics to a well-diversified portfolio.
ADMA Biologics Fundamentals Growth
ADMA Stock prices reflect investors' perceptions of the future prospects and financial health of ADMA Biologics, and ADMA Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ADMA Stock performance.
| Return On Equity | 0.36 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 3.91 B | ||||
| Shares Outstanding | 236.39 M | ||||
| Price To Earning | (1.55) X | ||||
| Price To Book | 16.74 X | ||||
| Price To Sales | 10.12 X | ||||
| Revenue | 258.21 M | ||||
| EBITDA | 5.12 M | ||||
| Cash And Equivalents | 52.42 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 141.42 M | ||||
| Debt To Equity | 1.32 % | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | 8.8 M | ||||
| Earnings Per Share | 0.27 X | ||||
| Total Asset | 329.18 M | ||||
| Retained Earnings | (506.26 M) | ||||
| Current Asset | 21.29 M | ||||
| Current Liabilities | 4.22 M | ||||
About ADMA Biologics Performance
By analyzing ADMA Biologics' fundamental ratios, stakeholders can gain valuable insights into ADMA Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ADMA Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ADMA Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Adma Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 527 people.Things to note about ADMA Biologics performance evaluation
Checking the ongoing alerts about ADMA Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ADMA Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ADMA Biologics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 258.21 M. Net Loss for the year was (28.24 M) with profit before overhead, payroll, taxes, and interest of 189.41 M. | |
| ADMA Biologics has a poor financial position based on the latest SEC disclosures | |
| Over 89.0% of the company shares are held by institutions such as insurance companies |
- Analyzing ADMA Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ADMA Biologics' stock is overvalued or undervalued compared to its peers.
- Examining ADMA Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ADMA Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ADMA Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ADMA Biologics' stock. These opinions can provide insight into ADMA Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |